Physician profile
Caleb Markusic
NPI 1538628607
$2,032.26
in general payments reported to CMS, 2019-2025
25 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.71 · 2022: $386 · 2023: $681 · 2024: $679 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,587.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $319.85 | 2022-2024 | Caplyta |
| Abbvie INC. | $295.00 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $212.82 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Evoke Pharma, INC. | $177.36 | 2022-2023 | Gimoti |
| Lundbeck LLC | $126.32 | 2022-2024 | Abilify Maintena, Rexulti |
| Axsome Therapeutics, INC. | $112.56 | 2022-2024 | Auvelity |
| Antares Pharma, INC. | $94.77 | 2024 | Xyosted |
| Halozyme INC | $86.43 | 2023 | |
| Gilead Sciences, INC. | $86.13 | 2024-2025 | |
| Alkermes, INC. | $65.97 | 2023 | Aristada, Vivitrol, Lybalvi |
| Genentech USA, INC. | $58.71 | 2021 | |
| Neurocrine Biosciences, INC. | $49.81 | 2023-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $47.48 | 2023 | Quviviq |
| Pfizer INC. | $45.98 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $45.53 | 2024-2025 | Austedo Xr, Austedo Xr |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $41.65 | 2024 | Fanapt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.45 | 2022 | |
| Novo Nordisk INC | $20.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $19.01 | 2023 | Invega Sustenna, Invega Trinza |
| Validus Pharmaceuticals LLC | $18.07 | 2023 | Equetro |
| E.R. Squibb & Sons, L.L.C. | $17.18 | 2024 | Cobenfy |
| Almatica Pharma LLC | $15.25 | 2023 | Loreev Xr |
| Lilly USA, LLC | $14.47 | 2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caleb Markusic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.